Next Article in Journal
Perceptions and Factors Affecting Pharmaceutical Market Access: Results from a Literature Review and Survey of Stakeholders in Different Settings
Previous Article in Journal
Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D

by
Julie Dorey
1,*,
Emilie Clay
1,
Amine Khemiri
2,
Anis Belhadj
2,
Patricia Trigo Cubillo
3 and
Mondher Toumi
4
1
Creativ-Ceutical, Paris, France
2
Creativ-Ceutical, Tunis, Tunisia
3
Neurology Department, Hospital Ramón y Cajal, Madrid, Spain
4
Facultéde Médecine, Laboratoire de Santé Publique, Aix-Marseille University, Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2016, 4(1), 27356; https://doi.org/10.3402/jmahp.v4.27356
Submission received: 21 January 2015 / Revised: 7 October 2015 / Accepted: 7 October 2015 / Published: 13 October 2016

Abstract

Background and objective: Huntington's disease (HD) is an inherited neurodegenerative disorder that heavily affects the patient's motor, cognitive, and psychological functions. Yet, very few studies have measured the impact of this disease on the patient's health-related quality of life (HRQoL) with specific and validated instruments. The aim of this study was to explore the impact of HD on the HRQoL of Spanish HD patients using the self-reported, Huntington Quality of Life Instrument (H-QoL-I) and the generic instrument EuroQoL five dimensions (EQ-5D-3L) and thereafter compare the results obtained with the two instruments. Methods: Fifty-five patients and an equal number of caregivers participated. Patient assessments included the questionnaires of the Huntington Self-Assessment Instrument's four parts: background information assessment, Huntington clinical self-reported instrument, disease-specific HRQoL assessment (H-QoL-I instrument) and Huntington resource utilisation interview, and the EQ-5D-3L questionnaire. Levels of disease severity were also determined based on the Unified Huntington's Disease Rating Scale that was completed by caregivers. Pearson's correlation tests were computed between H-QoL-I and EQ-5D-3L scores. Results: The scores obtained with the H-QoL-I instrument showed that motor dimension was the most altered followed by the psychological dimension while the social dimension was the least altered. Increase of disease severity resulted in lower patient QoL. The usual activities and anxiety/depression were the most severely altered dimensions according to the EQ-5D-3L results. Mobility was also altered to a great extent while pain was the least altered dimension. All correlations between H-QoL-I and EQ-5D-3L scores were moderate to high and statistically significant (p<0.01) with the exception of the correlation between H-QoL-I socialising score and EQ-5D-3L anxiety score. The highest correlations were found between H-QoL-I motor score and three EQ-5D-3L scores: mobility, self-care, and usual activity. Conclusions: The quality of life of the Spanish HD patients included in this study was severely affected by HD as demonstrated by the results of the generic EQ-5D-3L and the specific H-QoL-I instruments, which showed considerable impact of the disease on the motor and psychological functions. The H-QoL-I instrument was able to discern psychological and motor functioning dimensions that were altered by the disease with more specificity and accuracy than the generic instrument.
Keywords: Huntington's disease; health-related quality of life; instrument; EQ-5D-3L; H-QoL-I; self-reported outcomes; UHDRS independence scale Huntington's disease; health-related quality of life; instrument; EQ-5D-3L; H-QoL-I; self-reported outcomes; UHDRS independence scale

Share and Cite

MDPI and ACS Style

Dorey, J.; Clay, E.; Khemiri, A.; Belhadj, A.; Cubillo, P.T.; Toumi, M. The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D. J. Mark. Access Health Policy 2016, 4, 27356. https://doi.org/10.3402/jmahp.v4.27356

AMA Style

Dorey J, Clay E, Khemiri A, Belhadj A, Cubillo PT, Toumi M. The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D. Journal of Market Access & Health Policy. 2016; 4(1):27356. https://doi.org/10.3402/jmahp.v4.27356

Chicago/Turabian Style

Dorey, Julie, Emilie Clay, Amine Khemiri, Anis Belhadj, Patricia Trigo Cubillo, and Mondher Toumi. 2016. "The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D" Journal of Market Access & Health Policy 4, no. 1: 27356. https://doi.org/10.3402/jmahp.v4.27356

APA Style

Dorey, J., Clay, E., Khemiri, A., Belhadj, A., Cubillo, P. T., & Toumi, M. (2016). The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D. Journal of Market Access & Health Policy, 4(1), 27356. https://doi.org/10.3402/jmahp.v4.27356

Article Metrics

Back to TopTop